+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 453 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.

Age: 18Years +All GendersPhase 2
72 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.

Age: 18Years +All GendersPhase 2Phase 3
56 locations
S

Actively Recruiting

Researchers are evaluating MK-1045, an immunotherapy, for treating two types of non-Hodgkin lymphoma NHL follicular lymphoma FL, which grows slowly, and diffuse large B-cell lymphoma DLBCL, which grows quickly. NHL is a cancer of the lymphatic system causing swollen lymph nodes. The study aims to learn about the safety and tolerability of MK-1045 and whether it helps reduce or eliminate these lymphomas. Participants are randomly assigned to one of four groups receiving MK-1045 in different doses and methods intravenous IV infusion or subcutaneous SC injection. Treatment continues for up to approximately one year or until participants stop. The study includes phases 1b and 2 and involves optimizing doses and schedules, including longer dosing intervals and subcutaneous administration. During the study, participants will have regular assessments including monitoring for adverse events, response to treatment using the Lugano Response Criteria, and measuring drug levels in the body. Researchers will track safety up to about 49 months and monitor discontinuation due to side effects for up to 12 months. Tumor tissue samples and other laboratory tests will also be collected to understand treatment effects. The total participation can last several years with ongoing evaluations.

Age: 18Years +All GendersPhase 1Phase 2
52 locations
P

Actively Recruiting

Researchers are exploring new treatments for high-risk non-muscle invasive bladder cancer HR NMIBC, a type of cancer that affects the bladder lining without spreading to the bladder muscle or beyond. This research focuses on the safety and tolerability of MK-3120, a study drug, following the standard tumor removal procedure called transurethral resection of the bladder tumor TURBT. The study is a Phase 12 clinical trial investigating MK-3120 in people with HR NMIBC who are either Bacillus Calmette-Gurin BCG-nave or BCG-exposed. Participants will receive MK-3120 through intravesical administration, meaning the drug is delivered directly into the bladder. The treatment schedule begins with once-weekly doses for the first 6 weeks, followed by once-monthly doses for 9 months. This dosing plan aims to evaluate the drugs safety and effects over a period that includes the initial intensive phase and a maintenance phase. During the study, participants will be monitored closely for dose-limiting toxicities and adverse events up to about 24 months. Researchers will assess if participants discontinue treatment due to side effects within roughly 12 months. The main goal is to evaluate the safety profile of MK-3120 and observe its complete response rate up to approximately 3 months. Participants can expect regular assessments, including safety monitoring and treatment visits, throughout their involvement in the trial lasting several months to years.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
S

Actively Recruiting

Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.

Age: 18Years +FEMALEPhase 1Phase 2
40 locations
E

Actively Recruiting

Researchers are studying the safety and tolerability of Sacituzumab Tirumotecan when given directly into the bladder in people with intermediate-risk non-muscle invasive bladder cancer NMIBC. This phase 12 open-label study aims to find the highest dose participants can take without significant problems and to select a dose for future studies to evaluate how well the drug works. Participants will receive intravesical Sacituzumab Tirumotecan once a week for six weeks. The study may also include the use of rescue medications and supportive care measures to manage side effects. The study is designed as a single group where all participants receive the experimental treatment. During the study, participants will be closely monitored for dose-limiting toxicities and adverse events, with safety assessments over approximately 6 to 10 weeks. Researchers will also measure drug levels in the blood and evaluate treatment response up to 24 months. The total participation duration can be up to two years for some outcome measures.

Age: 18Years +All GendersPhase 1Phase 2
13 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.

Age: 12Years +All GendersPhase 3
63 locations
M

Actively Recruiting

Researchers are evaluating NXT007 prophylaxis compared with Factor VIII FVIII prophylaxis in people aged 12 years and older who have severe or moderate congenital hemophilia A without FVIII inhibitors. The study aims to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 in preventing bleeds compared to the standard FVIII treatment. Participants must have been on FVIII prophylaxis before joining the trial. Participants will be randomly assigned to receive either NXT007 prophylaxis or FVIII standard of care prophylaxis during the main study treatment period lasting six months. NXT007 is given by subcutaneous injection using a drug-device combination product, while FVIII is administered according to local dosing guidelines. After this period, those on NXT007 may continue its dosing, and those originally on FVIII can switch to NXT007 in an open-label extension phase. During the study, participants will be monitored regularly for bleeding rates, treatment burden, and quality of life using questionnaires like CATCH and TASQ. Safety will be assessed through adverse event monitoring, including injection-site reactions and thromboembolic events. Blood samples will be collected to measure NXT007 levels and immune response over approximately 3.5 years. The main outcome measured is the annualized bleed rate for treated bleeds over six months.

Age: 12Years +All GendersPhase 3
36 locations
E

Actively Recruiting

Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.

Age: 18Years +All GendersPhase 1Phase 2
91 locations

1-10 of 453

1